Pharmaceuticals company Eris Lifesciences announced Q1FY26 results Q1 Revenue: Rs 773 crore, change of 7.4%. Started ramping down Trade Gx business - Revenue down to Rs 3 crore in Q1FY26 vs Rs 13 crore in Q1FY25 - leading to an EBIDTA loss of Rs 5+ crore in Q1 (excluding DBF). Q1 EBIDTA: Rs 277 crore - margin expansion of 106 bps YoY from 34.7% to 35.8%, change 11% YoY. 20% YoY reduction in interest expense, from Rs 60 crore in Q1FY25 to Rs 49 crore in Q1FY26. Q1 PAT: Rs 125 crore, change 41% YoY, thereby kickstarting the 3-year cycle of EPS acceleration as per our guidance. Result PDF